Roche: positive phase III results in small cell lung cancer
(CercleFinance.com) - Roche said a late-stage trial of its monoclonal antibody Tecentriq met its co-primary endpoints of overall survival and progression-free survival with previously-untreated extensive-stage small cell lung cancer patients.
A phase III study enrolling 403 people demonstrated that initial treatment with the combination of Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer compared to chemotherapy alone.
The combination also reduced the risk of disease worsening or death compared to chemotherapy alone, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A phase III study enrolling 403 people demonstrated that initial treatment with the combination of Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer compared to chemotherapy alone.
The combination also reduced the risk of disease worsening or death compared to chemotherapy alone, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.